What is the price target for AVIR stock?
9 analysts have analysed AVIR and the average price target is 8.16 USD. This implies a price increase of 52.24% is expected in the next year compared to the current price of 5.36.
ATEA PHARMACEUTICALS INC (AVIR) Forecast, Price Target & Analyst Ratings
NASDAQ:AVIR • US04683R1068
Current stock price
5.36 USD
-0.11 (-2.01%)
At close:
5.36 USD
0 (0%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ATEA PHARMACEUTICALS INC (AVIR).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 13, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.60
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$8.16
Upside
+ 52.24%
From current price of $5.36 to mean target of $8.16, Based on 9 analyst forecasts
Low
$6.06
Median
$8.16
High
$10.50
Price Target Revisions
1 Month
33.33%
3 Months
33.33%
Price Target Summary
9 Wall Street analysts provided a forecast for the next 12 months for AVIR. The average price target is 8.16 USD. This implies a price increase of 52.24% is expected in the next year compared to the current price of 5.36.
The average price target has been revised upward by 33.33% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.22%
AVIR was analyzed by 9 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about AVIR.
In the previous month the buy percentage consensus was at a similar level.
AVIR was analyzed by 9 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-09 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-04-11 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2024-08-13 | Morgan Stanley | Upgrade | Underweight -> Equal-Weight |
| 2023-08-10 | JP Morgan | Downgrade | Neutral -> Underweight |
| 2023-03-16 | JP Morgan | Maintains | Neutral |
| 2023-01-27 | SVB Leerink | Maintains | Market Perform |
| 2023-01-24 | Morgan Stanley | Maintains | Underweight |
| 2022-08-15 | Morgan Stanley | Maintains | Underweight |
| 2022-03-02 | JP Morgan | Maintains | Neutral |
| 2022-03-01 | SVB Leerink | Maintains | Market Perform |
| 2022-02-16 | SVB Leerink | Maintains | Market Perform |
| 2022-01-06 | Morgan Stanley | Downgrade | Equal-Weight -> Underweight |
| 2021-11-18 | SVB Leerink | Downgrade | Outperform -> Market Perform |
| 2021-10-20 | SVB Leerink | Maintains | Outperform |
| 2021-10-20 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2021-10-05 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2021-09-09 | SVB Leerink | Initiate | Outperform |
| 2021-08-18 | Morgan Stanley | Maintains | Overweight |
| 2021-06-03 | Morgan Stanley | Maintains | Overweight |
| 2021-04-06 | Morgan Stanley | Maintains | Overweight |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 13, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.60
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- -50.45%
- Number of Analysts
- 4
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
-11.32%
Next Earnings Summary
AVIR is expected to report earnings on 5/13/2026. The consensus EPS estimate for the next earnings is -0.6 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates 2026 - 2028
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 48.6M | 351.4M 623.05% | -100.00% | 31.067M | 72.711M 134.05% | ||||||
| EBITDA YoY % growth | -14.6M -53.68% | 12M 182.19% | 231.9M 1,832.50% | -117.249M -147.82% | -141.259M -7.83% | -169.417M -10.03% | -142.676M -8.43% | -185.447M -29.98% | -110.143M 40.61% | -24.897M 77.40% | |
| EBIT YoY % growth | -14.6M -53.68% | 12M 182.19% | 231.9M 1,832.50% | -124.805M -147.95% | -168.393M -7.91% | -197.841M -10.00% | -175.44M -32.91% | -167.756M 4.38% | -130.111M 22.44% | -89.554M 31.17% | |
| Operating Margin | N/A | 24.69% | 65.99% | N/A | N/A | N/A | N/A | N/A | -418.81% | -123.16% | |
| EPS YoY % growth | N/A | N/A | 1.36 -4.99% | -1.46 -202.94% | -1.69 -17.14% | -2.00 -21.95% | -1.94 3.00% | -1.69 12.72% | -1.69 | -1.71 -1.20% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.60 -50.45% | -0.58 -32.14% | -0.53 -0.08% | -0.46 19.47% | -0.43 28.81% | -0.42 28.07% | -0.43 19.23% | -0.42 8.89% |
| Revenue Q2Q % growth | N/A | N/A | N/A | N/A | ||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -51M -34.90% | -49.98M -20.66% | -45.9M -0.98% | -40.8M 25.43% | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
3.75%
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
13.01%
EBIT Next 5 Year
17.00%
ATEA PHARMACEUTICALS INC / AVIR Forecast FAQ
When does ATEA PHARMACEUTICALS INC (AVIR) report earnings?
ATEA PHARMACEUTICALS INC (AVIR) will report earnings on 2026-05-13.
What are the consensus estimates for AVIR stock next earnings?
The consensus EPS estimate for the next earnings of ATEA PHARMACEUTICALS INC (AVIR) is -0.6 USD and the consensus revenue estimate is 0 USD.
How many analysts have analysed ATEA PHARMACEUTICALS INC (AVIR)?
The number of analysts covering ATEA PHARMACEUTICALS INC (AVIR) is 9.